Pandemic Darlings The pandemic economy, in original documents
Home Source documents Fulgent Genetics, Inc. Form 4 (May 25, 2021) — Xie JianSearch ⌕

Fulgent Genetics, Inc. Form 4 (May 25, 2021) — Xie Jian

Summary

Xie Jian, an officer of Fulgent Genetics, Inc. with the title Chief Operating Officer, reports on this Form 4 the sale of 2,000 shares of common stock on 05/25/2021 at a weighted-average sale price of $72.206. The shares were sold in multiple transactions at prices ranging from $72.20 to $72.24, inclusive. After the sale the reporting person owned 338,041 shares directly. The remarks show /s/ Paul Kim as Attorney-in-Fact, dated 05/27/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Fulgent Genetics, Inc. Form 4 (May 25, 2021) — Xie Jian.” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-flgt-4-filed2021-05-27-0001209191-21-036334-f405bab1eb/, SHA-256 37219eab0bbc39e41b5e8c0eaf91417931d75778187b0412ce595f8c9cc9c209.

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Xie Jian (Last) (First) (Middle) C/O FULGENT GENETICS, INC. 4978 SANTA ANITA AVE., STE 205 (Street) TEMPLE CITY CA 91780 (City) (State) (Zip) | Xie Jian | (Last) | (First) | (Middle) | C/O FULGENT GENETICS, INC. | 4978 SANTA ANITA AVE., STE 205 | TEMPLE CITY | CA | 91780 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Fulgent Genetics, Inc. [ FLGT ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Operating Officer | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Operating Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 05/25/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 05/25/2021 | S | 2,000 | D | $ 72.206 (1) | 338,041 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Explanation of Responses:
1. The shares were sold in multiple transactions at prices ranging from $72.20 to $72.24, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Remarks:
/s/ Paul Kim as Attorney-in-Fact | 05/27/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File
SEC_FLGT_4_filed2021-05-27_0001209191-21-036334.xml
Size
15,360 bytes
SHA-256
37219eab0bbc39e41b5e8c0eaf91417931d75778187b0412ce595f8c9cc9c209
Our copy
SEC_FLGT_4_filed2021-05-27_0001209191-21-036334.xml
Original
www.sec.gov
Back to top